Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment

Acute myeloid leukemia (AML) with t(8;21) is categorized as favorable-risk AML, but KIT mutations show a significantly poor prognostic impact in such patients. Persistent vulnerability to relapse is a major challenge in the treatment of this subtype of patients. Venetoclax is a BCL-2 selective inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zheng, Wang, Jun, Ge, Shuai-Shuai, Qiu, Qiao-Cheng, Du, Jia-Hui, Shan, Shuang-Shuang, Shen, Xiang-Dong, Wan, Chao-Ling, Wang, Bin-Ru, Wu, De-Pei, Qiu, Hui-Ying, Xue, Sheng-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861361/
https://www.ncbi.nlm.nih.gov/pubmed/35211416
http://dx.doi.org/10.3389/fonc.2022.841276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8861361/
https://www.ncbi.nlm.nih.gov/pubmed/35211416
http://dx.doi.org/10.3389/fonc.2022.841276

Ejemplares similares